New directions for biologic targets in urothelial carcinoma

Molecular Cancer Therapeutics

Volumn 11, Issue 6, 2012, Pages 1226-1235

  Richter, Suzanne ^a   Sridhar, Srikala S ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DOVITINIB; ERIBULIN; EVEROLIMUS; GEFITINIB; IXABEPILONE; LAROTAXEL; LONAFARNIB; METHOTREXATE; PACLITAXEL; PAZOPANIB; PRALATREXATE; SUNITINIB; TEMSIROLIMUS; TIPIFARNIB; VINFLUNINE; VOLASERTIB;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONFIDENCE INTERVAL; CYSTECTOMY; DISEASE COURSE; DRUG DEVELOPMENT; GENE MUTATION; HUMAN; MOLECULAR BIOLOGY; NICK END LABELING; NONHUMAN; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; STUDY DESIGN; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84862582329     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0756     Document Type: Review

References (75)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou- Redorta JAsociación Europea de Urología. [EAU guidelines on non-muscle-carcinoma of the bladder]. Actas Urol Esp 2009;33: 361-71.
3. Gontero P, Bohle A, Malmstrom PU, O'Donnell MA, Oderda M, Sylvester R, et al. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010; 57:410-29.
4. McKiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J Urol 2011;186:448-51.
5. Garcia JA, Stephenson AJ, Ireland J, Finke J, Elson P, Schaaf L, et al. Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Glickman Urological and Kidney Institute Cleveland Clinic, Cleveland, OH. Sunitinib in BCG-refractory non-muscle invasive transitional cell carcinona of the bladder. J Clin Oncol 29: 2011 (suppl 7; abstr 262).
6. ClinicalTrials.gov [homepage on the Internet]. Vancouver Coastal Health. A study for treatment of superficial bladder cancer using OGX-427. National Library of Medicine (US) 2000. [cited Jan 2012]. Available from: http://clinicaltrials.gov/show/NCT00959868 NLM Identifier: NCT00959868.
7. ClinicalTrials.gov [homepage on the Internet]. Roswell Park Cancer Institute. BCG plus interferon alfa 2b in treating patients with bladder cancer. National Library of Medicine (US) 2000. [cited Jan 2012]. Available from: http://clinicaltrials.gov/show/NCT00004122 NLM Identifier: NCT00004122.
8. ClinicalTrials.gov [homepage on the Internet]. Endo Pharmaceuticals. Mycobacterial cell wall-DNA complex in treatment of BCG-refractory patients with non-muscle invasive bladder cancer. Library of Medicine (US) 2000. [cited Jan 2012]. Available from: http://clinicaltrials.gov/ show/NCT00406068 NLM Identifier: NCT00406068.
9. Filion MC, PhillipsNC. Therapeutic potential of mycobacterial cell wall- DNA complexes. Expert Opin Investig Drugs 2001;10:2157-65. (Pubitemid 33150353)
10. van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol 2012;187:310-4.
11. Tomlinson DC, Hurst CD, Knowles MA. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007;26:5889-99.
12. Cheng L, Davidson DD, Maclennan GT, Williamson SR, Zhang S, Koch MO, et al. The origins of urothelial carcinoma. Expert Rev Anticancer Ther 2010;10:865-80.
13. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008;7:979-87.
14. Gallagher DJ, Bajorin DF. Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor. Nat Clin Pract Urol 2008;5:484-5.
15. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459-64, discussion 464-7.
16. Lehmann J, Franzaring L, Thüroff J, Wellek S, Stöckle M. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int 2006;97:42-7.
17. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005;48:189-99, discussion 199-201.
18. Ruggeri EM, Giannarelli D, Bria E, Carlini P, Felici A, Nelli F, et al. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. Cancer 2006;106:783-8. (Pubitemid 43238444)
19. Cognetti F, Ruggeri EM, Felici A, Gallucci M, Muto G, Pollera CF, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 2011:23;695-700.
20. Paz-Ares L, Solsona E, Esteban E, Saez A, Gonzalez-Larriba J, Anton A, et al. Randomized phase III trial comparing adjuvant paclitaxel/ gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 28:18s, 2010 (suppl; abstr LBA4518).
21. ClinicalTrials.gov [homepage on the Internet]. European Organization for Research and Treatment of Cancer - EORTC. Comparison of immediate and delayed adjuvant chemotherapy in treating patients who have undergone a radical cystectomy for stage III or stage IV transitional cell carcinoma of the bladder urothelium. National Library of Medicine (US) 2000. [cited Jan 2012]. Available from: http://clinicaltrials. gov/show/NCT00028756 NLM Identifier: NCT00028756.
22. ClinicalTrials.gov [homepage on the Internet]. Cancer and Leukemia Group B. Combination chemotherapy in treating patients with bladder cancer. National Library of Medicine (US) 2000. [cited Jan 2012]. Available from: http://clinicaltrials.gov/show/NCT00014534 NLM Identifier: NCT00014534.
23. Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011;29:3443-9.
24. International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999;354:533-40.
25. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MKInternational Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171-7.
26. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66. (Pubitemid 37025405)
27. Hsu T, North S, Eigl B, Chi K, Canil C, Wood L, et al. The neoadjuvant management of bladder cancer in Canada: a survey of genitourinary medical oncologists. J Clin Oncol 29: 2011 (suppl 7; abstr 285).
28. Feifer A, Taylor J, Shouery M, Steinberg G, Stadler W, Schoenberg M, et al. Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: phase I. J Clin Oncol 29: 2011 (suppl 7; abstr 240).
29. Smith D, Grivas P, Daignault S, Hafez K, WoodD, Lee C, et al. Aphase II trial of neoadjuvant ABI-007, carboplatin, and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladder. J Clin Oncol 29: 2011 (suppl 7; abstr 244).
30. ClinicalTrials.gov [homepage on the Internet]. Memorial Sloan-Kettering Cancer Center. Gemcitabine, cisplatin, and sunitinib (GC-S) as neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. [cited Jan 2012]. Available from: http://clinicaltrials. gov/show/NCT00847015NLM Identifier: NCT00847015.
31. ClinicalTrials.gov [homepage on the Internet]. Fondazione IRCCS Istituto Nazionale dei Tumori M. Cisplatin, gemcitabine hydrochloride, and sorafenib tosylate in treating patients with transitional cell cancer of the bladder. [cited Jan 2012]. Available from: http:// clinicaltrials.gov/show/NCT01222676NLM Identifier: NCT01222676.
32. ClinicalTrials.gov [homepage on the Internet]. MD Anderson Cancer Center. Neoadjuvant chemotherapy with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) plus avastin in patients with urothelial cancer. [cited Jan 2012]. Available from: http://clinicaltrials. gov/show/NCT00506155NLM Identifier: NCT00506155.
33. Chaudhary U, Golshayan A, Brisendine A, Kraft A, Clarke H, Keane T. Phase II trial of neoadjuvant cisplatin, gemcitabine, and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder. J Clin Oncol 29: 2011 (suppl 7; abstr 276).
34. Pruthi R, Kim W, Kurpad R, Heathcote S, Rathmell K, Whang Y, et al. A phase II study of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: preliminary clinical results. J Clin Oncol 27: 2009 (abstr 246).
35. Sonpavde G, Goldman BH, Speights VO, Lerner SP, Wood DP, Vogelzang NJ, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009;115: 4104-9.
36. Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. The National Cancer Institute of Canada Clinical Trials Group. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 1996; 14:2901-7. (Pubitemid 26371447)
37. James N, Hussain S, Hall H, Jenkins P, Tremlett J, Rawlings C, et al. Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004). J Clin Oncol 28:15s, 2010 (suppl; abstr 4517).
38. Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol 2011;29:733-8.
39. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-73.
40. Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, et al. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19:2638-46. (Pubitemid 32441368)
41. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
42. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-8. (Pubitemid 46224062)
43. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564-9. (Pubitemid 27289886)
44. Bellmunt J, von der Maase H, Mead G, Heyer J, Houede N, Paz-Ares L, et al. Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. J Clin Oncol 25:18s, 2010 (suppl; abstr LBA5030).
45. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy. J Clin Oncol 2011;29:2432-8.
46. ClinicalTrials.gov [homepage on the Internet]. California Cancer Consortium. E7389 in treating patients with locally advanced or metastatic cancer of the urothelium and kidney dysfunction. [cited Jan 2012]. Available from: http://clinicaltrials.gov/show/ NCT00365157NLM Identifier: NCT00365157.
47. Quinn D, Aparicio A, Tsao-Wei D, Groshen S, Dorff T, Synold T, et al. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC) - final report: a California Cancer Consortiumled NCI/CTEP-sponsored trial. J Clin Oncol 28:15s, 2010 (suppl; abstr 4539).
48. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II-results of EORTC study 30986. J Clin Oncol 2009;27:5634-9.
49. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:4454-61.
50. Sridhar S, Canil C, Mukherjee S, Winquist E, Elser C, Eisen A, et al. Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC). J Clin Oncol 29: 2011 (suppl 7; abstr 241).
51. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006;24:3451-7. (Pubitemid 46638903)
52. Streeter EH, Harris AL. Angiogenesis in bladder cancer - prognostic marker and target for future therapy. Surg Oncol 2002;11:85-100. (Pubitemid 34606008)
53. Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010;28:1373-9.
54. ClinicalTrials.gov [homepage on the Internet]. University of Michigan Cancer Center. Trial of maintenance SUO11248 versus placebo post chemotherapy for patients with advanced urothelial carcinoma. [cited Jan 2012]. Available from: http://clinicaltrials.gov/show/ NCT00393796NLM Identifier: NCT00393796.
55. Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E, Tannock IF, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs 2011;29:1045-9.
56. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009;115:4090-5.
57. Krege S, Rexer H, vom Dorp F, Albers P, De Geeter P, Klotz T. Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05). J Clin Oncol 28:15s, 2010 (suppl; abstr 4574).
58. Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, et al. Hoosier Oncology Group. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 2011; 29:1525-30.
59. ClinicalTrials.gov [homepage on the Internet]. Cancer and Leukemia Group B. Gemcitabine hydrochloride and cisplatin with or without bevacizumab in treating patients with advanced urinary tract cancer. [cited Jan 2012]. Available from: http://clinicaltrials.gov/show/ NCT00942331NLM Identifier: NCT00942331.
60. ClinicalTrials.gov [homepage on the Internet]. Mayo Clinic. Pazopanib in treating patients with metastatic urothelial cancer. [cited Jan 2012]. Available from: http://clinicaltrials.gov/show/NCT00471536 Identifier: NCT00471536.
61. ClinicalTrials.gov [homepage on the Internet]. Fondazione IRCCS Istituto Nazionale dei Tumori M. Pazopanib hydrochloride in treating patients with metastatic urethral cancer or bladder cancer that has relapsed or not responded to treatment. [cited Jan 2012]. Available from: http://clinicaltrials.gov/show/ NCT01031875 Identifier: NCT01031875.
62. ClinicalTrials.gov [homepage on the Internet]. Stanford University. Phase II pazopanib in combination with weekly paclitaxel in refractory urothelial cancer. [cited Jan 2012]. Available from: http://clinicaltrials. gov/show/NCT01108055 Identifier: NCT01108055.
63. Choueiri T, Vaishampayan U, Yu E, Quinn D, Hahn N, Hutson T, et al. A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer. J Clin Oncol 29: 2011 (suppl 7; abstr LBA239).
64. ClinicalTrials.gov [homepage on the Internet]. ImClone LLC. Study of ramucirumab or IMC-18F1 with docetaxel or docetaxel alone as second-line therapy in participants with bladder, urethra, ureter, or renal pelvis carcinoma. [cited Jan 2012]. Available from: http://clinicaltrials. gov/show/NCT01282463NLM Identifier: NCT01282463.
65. Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest 2010;90:1406-14.
66. Milowsky M, Carlson G, Shi M, Urbanowitz G, Zhang Y, Sternberg C. A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3. J Clin Oncol 29: 2011 (suppl; abstr TPS186).
67. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJCancer and Leukemia Group B. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009;20:1074-9.
68. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, et al. National Cancer Institute. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25:2218-24. (Pubitemid 46954646)
69. McHugh LA, Sayan AE, Mejlvang J, Griffiths TR, Sun Y, Manson MM, et al. Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. Int J Oncol 2009;34:1155-63.
70. Gomez-Abuin G, Winquist E, Stadler WM, Pond G, Degendorfer P, Wright J, et al. A phase II study of PS-341 (bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest New Drugs 2007;25:181-5. (Pubitemid 46020878)
71. Stadler W, Vaughn DJ, Sonpavde G, Vogelzang N, Tagawa S, Petrylak DP, et al. Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC). J Clin Oncol 29: 2011 (suppl; abstr 4567).
72. Metalli D, Lovat F, Tripodi F, Genua M, Xu SQ, Spinelli M, et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol 2010;176: 2997-3006.
73. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010;28:1850-5.
74. Smith SC, Baras AS, Lee JK, Theodorescu D. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res 2010;70:1753-8.
75. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 2009;4:e7887.